Post-earnings recap
Reported
Tue, Feb 26, 2013
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
United Therapeutics reported a strong EPS performance, exceeding expectations by 28%. The stock reacted positively, gaining 0.94%. The lack of revenue figures and guidance leaves some uncertainty, but the management's focus on growth and product development may reassure investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.60 | N/A | +28.00% |
| Revenue | N/A | N/A | N/A |
Management is pleased with the earnings results, particularly the EPS beat. They emphasized their commitment to innovation and growth.
Management expressed satisfaction with the EPS performance.
They highlighted ongoing efforts in product development.
Future growth potential remains a focus for the company.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—